STOCK TITAN

Philips to Further Roll Out RATE: AI for Early Infection Detection at U.S. Department of Defense Through Four-Year, $25 Million Contract

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
AI

Philips has secured a $25 million contract with the U.S. Department of Defense to expand its RATE (Rapid Analysis of Threat Exposure) algorithm over the next four years. The AI-powered technology uses biomarkers from wearables for early infection detection in military personnel. RATE's effectiveness was demonstrated in studies, including a 2022 research showing COVID-19 detection 2.3 days before symptoms appeared in 9,381 DoD personnel. The algorithm, initially developed in 2019, analyzed 163 biomarkers from 36,000 hospital-acquired infection cases to develop risk scores for various infections.

Philips ha ottenuto un contratto di 25 milioni di dollari con il Dipartimento della Difesa degli Stati Uniti per espandere il proprio algoritmo RATE (Rapid Analysis of Threat Exposure) nei prossimi quattro anni. La tecnologia supportata dall'intelligenza artificiale utilizza biomarcatori provenienti da dispositivi indossabili per la diagnosi precoce di infezioni nel personale militare. L'efficacia di RATE è stata dimostrata in vari studi, incluso uno del 2022 che mostrava una rilevazione del COVID-19 2,3 giorni prima della comparsa dei sintomi in 9.381 membri del DoD. L'algoritmo, sviluppato inizialmente nel 2019, ha analizzato 163 biomarcatori da 36.000 casi di infezioni acquisite in ospedale per elaborare punteggi di rischio per diverse infezioni.

Philips ha asegurado un contrato de 25 millones de dólares con el Departamento de Defensa de EE. UU. para expandir su algoritmo RATE (Análisis Rápido de la Exposición a Amenazas) durante los próximos cuatro años. La tecnología impulsada por inteligencia artificial utiliza biomarcadores de dispositivos portátiles para la detección temprana de infecciones en el personal militar. La efectividad de RATE se demostró en estudios, incluyendo una investigación de 2022 que mostraba una detección de COVID-19 2.3 días antes de la aparición de síntomas en 9,381 miembros del DoD. El algoritmo, desarrollado inicialmente en 2019, analizó 163 biomarcadores de 36,000 casos de infecciones adquiridas en hospitales para desarrollar puntuaciones de riesgo para diversas infecciones.

필립스는 향후 4년 동안 RATE(위협 노출의 신속한 분석) 알고리즘을 확대하기 위해 미국 국방부와 2,500만 달러의 계약을 체결했습니다. AI 기반 기술은 웨어러블 기기에서 수집한 바이오마커를 사용하여 군인들의 조기 감염 감지를 수행합니다. RATE의 효과는 여러 연구에서 입증되었으며, 2022년 연구에서는 9,381명의 국방부 직원에서 증상이 나타나기 2.3일 전 COVID-19를 감지하는 것으로 나타났습니다. 2019년에 처음 개발된 이 알고리즘은 병원에서 발생한 36,000건의 감염 사례에서 163개의 바이오마커를 분석하여 다양한 감염의 위험 점수를 개발했습니다.

Philips a obtenu un contrat de 25 millions de dollars avec le ministère de la Défense des États-Unis pour étendre son algorithme RATE (Analyse Rapide de l'Exposition aux Menaces) au cours des quatre prochaines années. La technologie alimentée par l'IA utilise des biomarqueurs provenant de dispositifs portables pour la détection précoce des infections chez le personnel militaire. L'efficacité de RATE a été démontrée dans plusieurs études, y compris une recherche de 2022 montrant une détection de COVID-19 2,3 jours avant l'apparition des symptômes chez 9.381 membres du DoD. L'algorithme, développé initialement en 2019, a analysé 163 biomarqueurs provenant de 36.000 cas d'infections acquises à l'hôpital pour développer des scores de risque pour diverses infections.

Philips hat einen Vertrag über 25 Millionen Dollar mit dem US-Verteidigungsministerium abgeschlossen, um seinen RATE (Rapid Analysis of Threat Exposure) Algorithmus in den nächsten vier Jahren auszubauen. Die KI-gestützte Technologie verwendet Biomarker von tragbaren Geräten zur frühzeitigen Erkennung von Infektionen bei Militärpersonal. Die Effektivität von RATE wurde in Studien nachgewiesen, einschließlich einer Forschung aus dem Jahr 2022, die zeigte, dass COVID-19 2,3 Tage vor dem Auftreten von Symptomen bei 9.381 DoD-Mitarbeitern erkannt wurde. Der Algorithmus, der ursprünglich 2019 entwickelt wurde, analysierte 163 Biomarker aus 36.000 Fällen von im Krankenhaus erworbenen Infektionen, um Risikopunkte für verschiedene Infektionen zu erstellen.

Positive
  • Secured $25 million contract with U.S. Department of Defense
  • Proven effectiveness in early COVID-19 detection (2.3 days before symptoms)
  • Large-scale validation with 9,381 DoD personnel
  • Technology compatible with commercial off-the-shelf wearables
Negative
  • None.

Insights

The $25 million DoD contract for RATE algorithm deployment represents a significant validation of Philips' AI-driven infection detection technology. The system's ability to detect COVID-19 infection 2.3 days before symptoms and up to 6 days prior in a large cohort of 9,381 DoD personnel demonstrates remarkable predictive capabilities. The algorithm's foundation on 163 biomarkers from 36,000 infection cases provides robust clinical validation. This technology could revolutionize military healthcare management and has potential commercial applications in civilian healthcare settings. The expansion from hospital-acquired infections to wearable-based monitoring shows promising scalability and accessibility.

The $25 million contract over four years, while modest relative to Philips' market cap, represents strategic value beyond its monetary worth. This DoD validation could catalyze broader commercial adoption in healthcare settings, potentially opening substantial market opportunities. The successful development from clinical to wearable applications demonstrates scalable commercialization potential. The technology's proven effectiveness in early detection could position Philips as a leader in predictive healthcare AI, particularly valuable in post-pandemic healthcare solutions. This could drive growth in Philips' connected care segment and enhance its competitive position in the digital health market.

After successful development and pilot, groundbreaking technology using biomarkers from wearables to predict infection is set to expand within the DoD

CAMBRIDGE, Mass. & WASHINGTON--(BUSINESS WIRE)-- Royal Philips (NYSE: PHG, AEX: PHIA) today announced it will accelerate the predictive health monitoring of the Rapid Analysis of Threat Exposure (RATE) algorithm to support the well-being and readiness of active-duty service personnel for the U.S. Department of Defense (DoD). Over the next four years, the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), will invest $25 million to make the technology more accessible in the field.

RATE, in advanced development, is an early detector of pre-symptomatic infection in humans. It is part of efforts to improve the readiness monitoring of active-duty personnel and has broad application in healthcare settings. The algorithm was developed as an early warning system that can reduce an individual’s downtime and aid in quickly containing the spread of disease by allowing exposed individuals to self-isolate or seek medical attention sooner.

“Our mission is to protect our troops and ensure we can quickly detect and prevent the spread of illness that can impact their wellbeing and our ability to protect our nation,” said Lorenzo Hankla, JPEO Wearables Program Officer. “Giving them the option of using readily available off-the-shelf wearables that are trained on clinical data allows them to passively monitor their health and quickly act if their infection score is high. In the wake of the pandemic, our troops need access to new AI-enabled technologies that can have a meaningful impact on their readiness and ensure overall military operations.”

The first version of the RATE algorithm, developed in 2019, used large-scale data science, machine learning, and trade-space analyses across demographics and 163 different biomarkers (vital signs and laboratory measurements) from a rich Philips data set of over 36,000 cases of hospital-acquired infections to develop a risk score. The risk score worked for multiple general types of infection, including common respiratory infections like pneumococcal pneumonia. These results were published in a 2023 study in Frontiers in Medicine.

A wearable version of the algorithm, prompted by the COVID-19 pandemic, leveraged biometric data from commercial-off-the-shelf wearables to enable early detection of infection. A 2022 study published in Nature’s Scientific Reports showed how, in a cohort of 9,381 DoD personnel, the algorithm was able to detect COVID-19 infection on average 2.3 days before symptoms appeared and up to six days prior. The study highlighted the utilization of algorithm-powered wearables to aid military readiness.

“Protecting the physical health and well-being of active service members is paramount,” said Jeff DiLullo, Chief Region Leader, Philips North America, and U.S. Army Veteran. “Our military personnel have unique care needs depending on their role and environment, and thanks to AI-enabled, predictive innovations like RATE, we can enable more timely intervention and personalized care, reducing downtime and improving outcomes – not only for individuals but entire units, too. The faster we diagnose and treat, the sooner these brave men and women are ready for duty.”

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About the JPEO-CBRND:

The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) mission is to provide an integrated layered chemical, biological, radiological, and nuclear defense capabilities to the joint force across combined Joint All-Domain Operations. JPEO-CBRND’s goal is to enable the joint force to fight and win unencumbered by a CBRN environment. To learn more about JPEO-CBRND, visit: https://www.jpeocbrnd.osd.mil/, or follow JPEO-CBRND on social media @JPEOCBRND.

Silvie Casanova

Philips North America

Tel: +1-781-879-0692

Email: silvie.casanova@philips.com

Avi Dines

Philips North America

Tel: +1-781 690 3814

Email: avi.dines@philips.com

Source: Royal Philips

FAQ

What is the value and duration of Philips (PHG) new DoD contract for RATE technology?

Philips secured a $25 million contract with the U.S. Department of Defense that will span over four years.

How early can Philips (PHG) RATE algorithm detect COVID-19 infection?

According to a 2022 study, the RATE algorithm can detect COVID-19 infection on average 2.3 days before symptoms appear and up to six days prior.

How many biomarkers does Philips (PHG) RATE algorithm analyze?

The RATE algorithm analyzes 163 different biomarkers, including vital signs and laboratory measurements, from a dataset of over 36,000 cases of hospital-acquired infections.

How many DoD personnel were involved in Philips (PHG) RATE algorithm study?

The 2022 study published in Nature's Scientific Reports included a cohort of 9,381 Department of Defense personnel.

KONINKLIJKE PHILIPS N.V.

NYSE:PHG

PHG Rankings

PHG Latest News

PHG Stock Data

24.39B
939.94M
7.11%
0.25%
Medical Devices
Healthcare
Link
United States of America
Amsterdam